Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Authors
Gore, MSzczylik, C
Porta, C
Bracarda, S
Bjarnason, G
Oudard, S
Lee, S
Haanen, J
Castellano, D
Vrdoljak, E
Schöffski, P
Mainwaring, P
Hawkins, Robert E
Crinò, L
Kim, T
Carteni, G
Eberhardt, W
Zhang, K
Fly, K
Matczak, E
Lechuga, M
Hariharan, S
Bukowski, R
Issue Date
2015-06-30
Metadata
Show full item recordAbstract
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.Citation
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. 2015, 113 (1):12-9 Br J CancerJournal
British Journal of CancerDOI
10.1038/bjc.2015.196PubMed ID
26086878Type
ArticleLanguage
enISSN
1532-1827ae974a485f413a2113503eed53cd6c53
10.1038/bjc.2015.196